Rose Cunningham-Ahumada
Ophthalmology · Santa Ana, CANPI 1811996523
Payments from drug & device makers
Across 103 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$876
- AbbVie$508
- Alcon$441
- Bausch & Lomb Americas Inc.$113
- Thea Pharma Inc.$105
- Sun Pharmaceutical Industries Inc.$100
- plus $592 from 12 others
What the payments were for
- Food & beverage$2,734100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $876 |
| AbbVie(2 entities) | 31 | $508 |
| Alcon | 14 | $441 |
| Bausch & Lomb Americas Inc. | 1 | $113 |
| Thea Pharma Inc. | 5 | $105 |
| Sun Pharmaceutical Industries Inc. | 4 | $100 |
| Glaukos Corporation | 1 | $83 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $80 |
| Dompe US, Inc. | 3 | $74 |
| Novartis | 3 | $68 |
| Ocular Therapeutix, Inc. | 3 | $58 |
| Rayner Intraocular Lenses Limited | 2 | $56 |
| Shire North American Group Inc | 2 | $45 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $36 |
| Sight Sciences, Inc. | 2 | $33 |
| Rxsight Inc | 1 | $24 |
| Boston Scientific | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,734 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 212 | $147,340 |
| XiidraLifitegrast | 83 | $71,006 |
| Cyclosporine | 154 | $58,620 |
| LumiganBimatoprost | 75 | $29,345 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $10,260 |
| Timolol Maleate | 169 | $7,672 |
| Prednisolone Acetate | 220 | $7,428 |
| RhopressaNetarsudil Mesylate | 18 | $6,902 |
| Alphagan PBrimonidine Tartrate | 26 | $5,730 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 64 | $5,364 |
| Latanoprost | 592 | $5,136 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $4,704 |
| Loteprednol Etabonate | 25 | $4,620 |
| Methazolamide | 17 | $3,919 |
| Ketorolac Tromethamine | 173 | $3,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $508 | $187,119336 claims |
| Bausch & Lomb Americas Inc.Xiidra | $113 | $71,00683 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $17 | $17,16236 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $80 | $4,62025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Santa Ana
- Sanford ChenSanta Ana$2.3M
- Michael SheetySanta Ana$642K
- Timothy YouSanta Ana$608K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.